A 62-year-old man with a 17-year history of type 2 diabetes had been receiving treatment with metformin (2000 mg/day), gliclazide (40 mg/day), liraglutide (0.9 mg/day), and the SGLT2 inhibitor empagliflozin (25 mg/day). Here, SLC5A2 is linked to type 2 diabetes mellitus.